IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
Key Highlights
- ➤ChoICE Study adds Legacy Health’s Good Samaritan Medical Center as a U.S. clinical site
- ➤FDA-approved post-market study targets approximately 400 patients across up to 30 U.S. sites
- ➤Nathalie Johnson named co-primary investigator for Legacy Good Samaritan’s study participation
- ➤ProSense® evaluates minimally invasive cryoablation for eligible low-risk breast cancer patients
Expert Statements
Eyal Shamir, Chief Executive Officer of IceCure Medical
“As a nationally recognized breast cancer expert, we are excited to welcome Dr. Nathalie Johnson and the Legacy Good Samaritan site to the ChoICE Study”
Eyal Shamir, Chief Executive Officer of IceCure Medical
“With Dr. Johnson serving as Co-Primary Investigator, we believe her background, experience and expertise, in addition to the inclusion of the Legacy Good Samaritan site represents an important milestone for the study.”
Eyal Shamir, Chief Executive Officer of IceCure Medical
“We deeply value her clinical leadership and look forward to continuing our collaboration as we expand patient access and bolster the clinical evidence supporting cryoablation for low-risk breast cancer.”
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site PR Newswire
CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition of Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE Study") evaluating the use of ProSense® cryoablation in the local treatment of low-risk breast cancer.
Get started
Create a free account to read the full story.